Interconnections between the Gut Microbiome and Alzheimer’s Disease: Mechanisms and Therapeutic Potential DOI Open Access
Ahmad M Sait, Philip J. Day

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8619 - 8619

Published: Aug. 7, 2024

Alzheimer’s disease (AD) is a neurodegenerative that known to accumulate amyloid-β (Aβ) and tau protein. Clinical studies have not identified pathogenesis mechanisms or produced an effective cure for AD. The Aβ monoclonal antibody lecanemab reduces plaque formation the treatment of AD, but more are required increase effectiveness drugs reduce cognitive decline. lack AD therapy targets evidence association with acute neuroinflammatory response caused by several bacteria viruses in some individuals has led establishment infection hypothesis during last 10 years. How pathogens cross blood–brain barrier highly topical seen be pivotal proving hypothesis. This review summarizes possible role gut microbiome feasible therapeutic approaches current research limitations.

Language: Английский

Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease DOI Creative Commons

Kathryn A Conn,

Emily M. Borsom, Emily K. Cope

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: July 15, 2024

The gut microbial ecosystem communicates bidirectionally with the brain in what is known as gut-microbiome-brain axis. Bidirectional signaling occurs through several pathways including via vagus nerve, circulation of metabolites, and immune activation. Alterations microbiota are implicated Alzheimer's disease (AD), a progressive neurodegenerative disease. Perturbations communities may affect within axis altered production metabolites ɣ-aminobutyric acid (GABA), primary inhibitory mammalian neurotransmitter. GABA has been shown to act on integrity modulation mucins tight junction proteins be involved nerve signal inhibition. GABAergic pathway dysregulated AD, responsive interventions. Gut recent interest neurological disorders, AD. Bacteroides Lactic Acid Bacteria (LAB), Lactobacillus, predominant producers GABA. This review highlights how temporal alterations associated AD pathway, intestinal barrier integrity, AD-associated inflammation.

Language: Английский

Citations

18
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization DOI Creative Commons
Amanda M. Leisgang Osse,

Jefferson W. Kinney,

Jeffrey L. Cummings

et al.

Alzheimer s & Dementia Translational Research & Clinical Interventions, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 1, 2025

Language: Английский

Citations

2
Lipid-Lowering Medications are Associated with Reduced Sarcopenia-Related Quality of Life in Older Adults with Hyperlipidemia DOI
Rizwan Qaisar,

Imran M. Khan,

Asima Karim

et al.

Drugs & Aging, Journal Year: 2024, Volume and Issue: 41(5), P. 443 - 453

Published: April 2, 2024

Language: Английский

Citations

5
Butyrate supplementation reduces sarcopenia by repairing neuromuscular junction in patients with chronic obstructive pulmonary disease DOI
Rizwan Qaisar, Asima Karim, Tahir Muhammad

et al.

Respiratory Medicine, Journal Year: 2023, Volume and Issue: 222, P. 107510 - 107510

Published: Dec. 22, 2023

Language: Английский

Citations

13
Butyrate (short-chain fatty acid) alleviates lipopolysaccharide-binding proteins and improves physical function in knee osteoarthritis patients DOI
Asima Karim, Haroon Ahmed Khan, Firdos Ahmad

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 307, P. 142017 - 142017

Published: March 11, 2025

Language: Английский

Citations

0
Angiotensin Receptor Blockers Improve Sarcopenia-related Quality of Life by Repairing Intestinal Leak in Patients with Chronic Kidney Disease DOI
Rizwan Qaisar,

Ayousha Burki,

Asima Karim

et al.

SN Comprehensive Clinical Medicine, Journal Year: 2025, Volume and Issue: 7(1)

Published: April 24, 2025

Language: Английский

Citations

0
Interconnections between the Gut Microbiome and Alzheimer’s Disease: Mechanisms and Therapeutic Potential DOI Open Access
Ahmad M Sait, Philip J. Day

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8619 - 8619

Published: Aug. 7, 2024

Alzheimer’s disease (AD) is a neurodegenerative that known to accumulate amyloid-β (Aβ) and tau protein. Clinical studies have not identified pathogenesis mechanisms or produced an effective cure for AD. The Aβ monoclonal antibody lecanemab reduces plaque formation the treatment of AD, but more are required increase effectiveness drugs reduce cognitive decline. lack AD therapy targets evidence association with acute neuroinflammatory response caused by several bacteria viruses in some individuals has led establishment infection hypothesis during last 10 years. How pathogens cross blood–brain barrier highly topical seen be pivotal proving hypothesis. This review summarizes possible role gut microbiome feasible therapeutic approaches current research limitations.

Language: Английский

Citations

1